Burlingame, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The global Substance Abuse Treatment Market, valued at $11.8 billion in 2023, is on a trajectory of rapid expansion, with projections indicating it will soar to $22.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2023 to 2031, as per a recent report by Coherent Market Insights. Rising addiction rates can be attributed to various factors such as greater social acceptance of substance use, increased availability of illicit drugs, stress and mental health issues. As more individuals develop dependencies, it is fueling the demand for effective treatment options. Various treatment modalities are available including inpatient, outpatient and medication therapies. This growing patient pool diagnosed with substance abuse is a major driver propelling the substance abuse treatment market forward.
Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/6671
Market Dynamics:
The global substance abuse treatment market is witnessing significant growth owing to rising prevalence of drug and substance abuse across the world. According to World Drug Report 2022 by United Nations Office on Drugs and Crime, around 36.3 million people around the world suffer from drug use disorders and around 686,000 people died as a result of drug use in 2020. Moreover, alcohol is the world’s third leading cause of ill health and premature death.Easy availability of drugs and peer pressure are some of the key drivers augmenting the growth of substance abuse globally. Growing acceptance and funding for innovative treatment options such as digital therapeutic is additionally boosting the market growth.
Global Substance Abuse Treatment Market Report Coverage
Report Coverage | Details |
Market Revenue in 2023 | $11.8 billion |
Estimated Value by 2031 | $22.8 billion |
Growth Rate | Poised to grow at a CAGR of 8.6% |
Historical Data | 2019–2023 |
Forecast Period | 2024–2031 |
Forecast Units | Value (USD Million/Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | By Type, By Treatment Type, By Age Group, By Treatment Setting |
Geographies Covered | North America, Europe, Asia Pacific, and Rest of World |
Growth Drivers | • Increasing consumption of drugs and alcohol • Growing support from government and NGOs |
Restraints & Challenges | • Social stigma associated with substance dependence • Lack of adequate rehabilitation facilities |
Market Trends:
Drug de-addiction and alcohol de-addiction centers are increasingly adopting digital therapeutics to provide remote treatment and monitoring to patients. Advent of wearable biosensing devices and mobile applications that help in monitoring drug and alcohol intake in patients are gaining popularity in substance abuse treatment. For instance, Dance Biopharm has developed Saliva Test Strip which provides immediate color result if drug is present in saliva. Additionally, Orexo's vorvida digital therapeutic platform provides at-home substance use disorder treatment plan using mobile tools. Growing adoption of such digital innovations is expected to define the future growth path of global substance abuse treatment market during the forecast period.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6671
The rates of substance abuse have been steadily rising across both developed and developing nations over the past decade. According to the World Drug Report 2022, around 275 million people globally used drugs at least once during 2021. The most commonly abused substances included opioids, cocaine, cannabis, amphetamines and new psychoactive substances. This dramatic rise in substance abuse cases has led to a growing demand for effective treatment and rehabilitation services.
Leading drug makers are pumping millions into R&D to develop more effective and advanced therapeutic drugs for substance abuse treatment. For instance, in 2021, Indivior announced FDA approval for Perseris, a long-acting injectable medication for schizophrenia treatment in adults. The drug helps reduce symptoms and lessens the risk of relapse due to substance abuse. Similarly, Teva launched a generic version of Suboxone film, used for opioid dependence treatment. The launch of such innovative drugs is expected to drive the overall market growth in the coming years.
Key Market Takeaways:
The global substance abuse treatment market is anticipated to witness a CAGR of 8.6% during the forecast period 2024-2031, owing to the increasing prevalence of drug abuse worldwide.
On the basis of type, alcohol segment is expected to hold a dominant position, owing to its widespread harmful use.
On the basis of treatment type, opioid segment is expected to hold a major share during the forecast period, due to the rising opioid addiction rates globally.
On the basis of age group, adolescents segment is anticipated to emerge as the largest segment over the coming years, driven by rising experimentation of drugs at a young age.
On the basis of treatment setting, outpatient treatment is anticipated to be the most preferred setting, as it offers convenience and low costs.
By region, North America is expected to hold a dominant position over the forecast period, due to high healthcare expenditure and presence of key market players in the region.
Key players operating in the global substance abuse treatment market include Indivior PLC, Pfizer, Inc., Johnson & Johnson Inc., Alkermes, Mallinckrodt Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. Strategic collaborations and new product launches are some of the key strategies adopted by these companies to gain a competitive edge in the market.
Recent Developments:
In January 2023, Tempero Bio, received approval from the US. FDA for its investigational new drug application for TMP-301, a lead candidate that is used for indication of treatment of cocaine use disorder.
In May 2023, Camurus announced that the US Food and Drug Administration has approved Brixadi extended release injection for subcutaneous use, a weekly and monthly medication for the treatment of moderate to serve opioid use disorder.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/6671
Detailed Segmentation:
By Type:
- Alcohol
- Opioids (e.g., heroin, prescription painkillers)
- Tobacco/nicotine
- Cocaine
- Marijuana
- Methamphetamines
- Other illicit drugs (Benzodiazepines, etc.)
By Treatment Type:
- Opioid
- Methadone
- Buprenorphine
- Extended-release naltrexone
- Lofexidine
- Nicotine
- Nicotine replacement therapies (available as a patch, inhaler, or gum)
- Bupropion
- Varenicline
- Alcohol
- Naltrexone
- Disulfiram
- Acamprosate
- Tobacco
- Clonidine
- Nortriptyline
- Others (Topiramate, Modafinil, etc.)
By Age Group:
- Adolescents
- Adults
- Geriatric
By Treatment Setting:
- Outpatient Treatment
- Outpatient Clinics
- Private Practices
- Inpatient Treatment
- Rehabilitation Centers
- Hospitals
- Residential Treatment Facilities
- Detoxification Centers
By Region:
North America:
- U.S.
- Canada
Latin America:
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe:
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East:
- GCC Countries
- Israel
- Rest of Middle East
Africa:
- South Africa
- North Africa
- Central Africa
Browse Related Reports:
Global Geriatric Medicines Market: Global geriatric medicines market is estimated to be valued at USD 1,004.71 Bn in 2024 and is expected to reach USD 1,570.18 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.
Global Menopause Treatment Market: The global menopause treatment market was valued US$ 15.33 Bn in 2023 and is expected to reach US$ 24.33 Bn by 2031 growing at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Global Bronchodilators Market: The global bronchodilators market was valued US$ 22.85 Bn in 2023 and is expected to reach US$ 30.44 Bn by 2031, growing at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031.
H2 Receptor Antagonist Market: The H2 receptor antagonist Market is estimated to be valued at USD 4.21 Bn in 2024 and is expected to reach USD 6.36 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
Author Bio:
Money Singh is a seasoned PR writer with over four years of experience in the market research sector. Known for her strong SEO background, she skillfully blends SEO strategies with insightful content. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (LinkedIn: https://www.linkedin.com/in/money-singh-590844163)
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.